MaxCyte, Inc. Appointment of Amanda L. Murphy as CFO (3947Y)
September 09 2020 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 3947Y
MaxCyte, Inc.
09 September 2020
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer
and
Names Ron Holtz as Senior Vice President & Chief Accounting
Officer
- Murphy brings a wealth of life sciences capital markets
experience and deep knowledge in the enabling technologies and cell
therapy sectors
- Holtz to remain on the Board of Directors of the Company and
retain key elements of his executive role, including overseeing
accounting, budgeting, and supporting key business operations
Gaithersburg, Maryland - 9 September 2020: MaxCyte, Inc. (LSE:
MXCT, MXCL), a global cell-based therapies and life sciences
company, announced today that Amanda L. Murphy, CFA, has joined the
Company as Chief Financial Officer (CFO). Ron Holtz, who has served
as MaxCyte's CFO since 2005, will become Senior Vice President and
Chief Accounting Officer (SVP & CAO).
Before joining MaxCyte, Ms. Murphy served as a Managing Director
of BTIG, LLC. She has specialized in gene therapy, gene editing and
cell therapy equity research for both burgeoning private and
established public healthcare companies. Prior to BTIG, she was a
Partner and Healthcare Analyst at William Blair & Company,
focused on diagnostic services and life sciences. She received a BS
in biology from Boston College's honors program, and an MBA in
finance, accounting and economics from the Kellogg Graduate School
of Management at Northwestern University.
MaxCyte President & CEO, Doug Doerfler, said: "We are
extremely pleased to welcome Amanda, who served as a successful,
respected analyst in both the enabling technology and cell therapy
sectors, to the MaxCyte team at this pivotal moment for the Company
and the industry. We are collectively witnessing the beginning of
cell and gene therapies' impact on revolutionizing medical
treatment and saving human lives, and Amanda's w ealth of
experience - her deep understanding of the financial community and
her unique, insightful, strategic view of the cell therapy sector -
will support the continued development and expansion of MaxCyte's
contribution in this space."
Ms. Murphy commented, "From my work as a healthcare analyst,
I've long been familiar with MaxCyte's central role in the cell
therapy space, as the inventors of the premier cell engineering
enabling technology and the go-to partner for the world's leading
gene editing and cell therapy companies. It's exciting to join
MaxCyte at this time, as the cell therapy industry continues to
accelerate the development of advanced life-saving therapies, and
as the Company looks to evolve its business model with the spin-off
of CARMA Cell Therapies(TM) and a potential listing on the Nasdaq
exchange."
In his new role as CAO and SVP, Ron Holtz, will retain key
elements of his former role as CFO, including overseeing accounting
and budgeting/forecasting and supporting key business operations.
The Board of Directors is unchanged with Mr. Holtz remaining as an
Executive member of the Board.
Mr. Holtz noted, "As MaxCyte grows, evolves, and prepares for
entry into the US public equity market, it's the ideal time for us
to bring in someone with Amanda's unique capital markets
perspective and deep insights into the cell tharapy space. I am
also looking forward to continuing to focus where my primary
interests and skillsets can best support MaxCyte's future."
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com .
###
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUWRBRROUKRAR
(END) Dow Jones Newswires
September 09, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024